Fig 4.
Kaplan-Meier log-rank survival analysis for CHD7 expression in patients receiving adjuvant therapy (n=59) and in patients receiving gemcitabine therapy (n=42). (A) Effect of CHD7 expression on recurrence-free survival (RFS) in patients receiving gemcitabine therapy (n=42). (B) Effect of CHD7 expression on overall survival (OS) in patients receiving gemcitabine therapy (n=42). (C) Effect of CHD7 expression on RFS in patients receiving adjuvant therapy (n=59). (D) Effect of CHD7 expression on OS in patients receiving adjuvant therapy (n=59).